$GRTX
Galera Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063361 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.987M $4.990M
YoY Change -60.43% 2.82%
% of Gross Profit
Research & Development $3.189M $6.093M
YoY Change -60.81% -24.83%
% of Gross Profit
Depreciation & Amortization $219.0K $10.00K
YoY Change 742.31% -62.96%
% of Gross Profit
Operating Expenses $5.176M $6.093M
YoY Change -60.66% -24.83%
Operating Profit -$13.40M
YoY Change 3.37%
Interest Expense -$411.0K -$2.087M
YoY Change -86.63% -164.31%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.587M -$15.07M
YoY Change -65.64% -6.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.587M -$15.07M
YoY Change -65.49% -5.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$0.10 -$0.33
COMMON SHARES
Basic Shares Outstanding 54.39M 43.93M
Diluted Shares Outstanding 45.48M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.26M $28.40M
YoY Change -42.22% -33.6%
Cash & Equivalents $18.26M $24.38M
Short-Term Investments $0.00 $4.000M
Other Short-Term Assets $3.372M $2.900M
YoY Change -51.4% 35.01%
Inventory
Prepaid Expenses $1.450M
Receivables
Other Receivables
Total Short-Term Assets $21.63M $31.25M
YoY Change -43.87% -30.44%
LONG-TERM ASSETS
Property, Plant & Equipment $1.283M $198.0K
YoY Change 192.92% -57.33%
Goodwill $881.0K $881.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $1.948M
YoY Change -95.22% -6.66%
Total Long-Term Assets $4.512M $6.534M
YoY Change -17.98% 12.73%
TOTAL ASSETS
Total Short-Term Assets $21.63M $31.25M
Total Long-Term Assets $4.512M $6.534M
Total Assets $26.14M $37.78M
YoY Change -40.64% -25.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.375M $3.715M
YoY Change -61.6% 3.45%
Accrued Expenses $3.582M $8.784M
YoY Change -63.28% 10.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.957M $12.63M
YoY Change -62.95% 8.58%
LONG-TERM LIABILITIES
Long-Term Debt $151.0M $150.3M
YoY Change 8.17% 10.26%
Other Long-Term Liabilities $1.117M $1.200M
YoY Change
Total Long-Term Liabilities $152.2M $151.5M
YoY Change 8.97% 11.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.957M $12.63M
Total Long-Term Liabilities $152.2M $151.5M
Total Liabilities $157.3M $164.3M
YoY Change 2.68% 10.87%
SHAREHOLDERS EQUITY
Retained Earnings -$437.4M -$431.8M
YoY Change 15.62% 19.25%
Common Stock $306.2M $305.3M
YoY Change 13.77% 15.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$131.2M -$126.6M
YoY Change
Total Liabilities & Shareholders Equity $26.14M $37.78M
YoY Change -40.64% -25.5%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.587M -$15.07M
YoY Change -65.49% -5.99%
Depreciation, Depletion And Amortization $219.0K $10.00K
YoY Change 742.31% -62.96%
Cash From Operating Activities -$9.918M -$12.52M
YoY Change -28.88% 35.94%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $3.982M $10.47M
YoY Change 43.29% 127.16%
Cash From Investing Activities $3.973M $10.47M
YoY Change 42.97% 127.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -234.0K 2.140M
YoY Change -108.66% 21300.0%
NET CHANGE
Cash From Operating Activities -9.918M -12.52M
Cash From Investing Activities 3.973M 10.47M
Cash From Financing Activities -234.0K 2.140M
Net Change In Cash -6.179M 90.00K
YoY Change -27.0% -101.96%
FREE CASH FLOW
Cash From Operating Activities -$9.918M -$12.52M
Capital Expenditures $9.000K $0.00
Free Cash Flow -$9.927M -$12.52M
YoY Change -28.81% 36.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Liberty Blvd, Suite 230
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
dei Trading Symbol
TradingSymbol
GRTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54392170
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24379000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4266000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
3985000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
27331000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
50000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
50000
CY2023Q3 grtx Refundable Pdufa Fee
RefundablePdufaFee
0
CY2022Q4 grtx Refundable Pdufa Fee
RefundablePdufaFee
3242000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2831000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3646000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
31245000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38535000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
438000
CY2023Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2023Q3 us-gaap Goodwill
Goodwill
881000
CY2022Q4 us-gaap Goodwill
Goodwill
881000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1249000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1948000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1881000
CY2023Q3 us-gaap Assets
Assets
37779000
CY2022Q4 us-gaap Assets
Assets
44036000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3715000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3581000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8784000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9754000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
131000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
44000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12630000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13379000
CY2023Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
150344000
CY2022Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
139635000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1155000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q3 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
203000
CY2022Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
203000
CY2023Q3 us-gaap Liabilities
Liabilities
164332000
CY2022Q4 us-gaap Liabilities
Liabilities
153217000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53734123
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53734123
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28510066
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28510066
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
54000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305212000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
269137000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-431819000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-378324000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-126553000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-109181000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37779000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44036000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6093000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8105000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20926000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22848000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4994000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4853000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20849000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15193000
CY2023Q3 us-gaap Other Restructuring Costs
OtherRestructuringCosts
2309000
CY2022Q3 us-gaap Other Restructuring Costs
OtherRestructuringCosts
0
us-gaap Other Restructuring Costs
OtherRestructuringCosts
2309000
us-gaap Other Restructuring Costs
OtherRestructuringCosts
0
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13396000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12958000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44084000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38041000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
411000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
171000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1300000
us-gaap Investment Income Interest
InvestmentIncomeInterest
256000
CY2023Q3 us-gaap Interest Expense
InterestExpense
-2087000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3245000
us-gaap Interest Expense
InterestExpense
10709000
us-gaap Interest Expense
InterestExpense
8247000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
us-gaap Net Income Loss
NetIncomeLoss
-53495000
us-gaap Net Income Loss
NetIncomeLoss
-46034000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45477952
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45477952
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26823546
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26823546
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41234679
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41234679
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26798348
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26798348
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
us-gaap Net Income Loss
NetIncomeLoss
-53495000
us-gaap Net Income Loss
NetIncomeLoss
-46034000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-79000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15078000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16016000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53473000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46113000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-109181000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1458000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000
CY2023Q1 grtx Common Stock Issuance Costs
CommonStockIssuanceCosts
2403000000
CY2023Q1 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
27598000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17710000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97613000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1525000
CY2023Q2 grtx Stock Issued During Period Value Common Stock Warrants Exercised1
StockIssuedDuringPeriodValueCommonStockWarrantsExercised1
1812000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20712000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114999000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1390000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q3 grtx Stock Issued During Period Value Common Stock Warrants Exercised1
StockIssuedDuringPeriodValueCommonStockWarrantsExercised1
197000
CY2023Q3 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
-1933000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-126553000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-58004000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1848000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2022Q1 grtx Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
1117000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15443000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-70471000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14558000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-83246000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1750000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16033000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-97502000
us-gaap Profit Loss
ProfitLoss
-53495000
us-gaap Profit Loss
ProfitLoss
-46034000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000
us-gaap Paid In Kind Interest
PaidInKindInterest
10709000
us-gaap Paid In Kind Interest
PaidInKindInterest
8247000
us-gaap Share Based Compensation
ShareBasedCompensation
4373000
us-gaap Share Based Compensation
ShareBasedCompensation
5428000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
72000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
grtx Refundable Pdufa Fees
RefundablePdufaFees
3242000
grtx Refundable Pdufa Fees
RefundablePdufaFees
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1133000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4077000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-60000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
134000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1453000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-970000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
68000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
193000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34933000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29481000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22627000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
46920000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
45995000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
68160000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23318000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21215000
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
27598000
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
0
grtx Proceeds From The Sale Of Common Stock Under The Open Market Sale Agreement
ProceedsFromTheSaleOfCommonStockUnderTheOpenMarketSaleAgreement
1933000
grtx Proceeds From The Sale Of Common Stock Under The Open Market Sale Agreement
ProceedsFromTheSaleOfCommonStockUnderTheOpenMarketSaleAgreement
1117000
grtx Proceeds From The Exercise Of Common Stock Warrants
ProceedsFromTheExerciseOfCommonStockWarrants
2009000
grtx Proceeds From The Exercise Of Common Stock Warrants
ProceedsFromTheExerciseOfCommonStockWarrants
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
188000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31728000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1187000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20113000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7079000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4316000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19859000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24429000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12780000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1310000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
319000
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
0
CY2023Q3 grtx Number Of Reduction In Companys Current Workforce Employees
NumberOfReductionInCompanysCurrentWorkforceEmployees
22
CY2023Q3 grtx Workforce Reduction Rate
WorkforceReductionRate
0.70
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-431800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
50000
CY2022Q4 grtx Refundable Pdufa Fee
RefundablePdufaFee
3200000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1600000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1696164
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.92
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6387121
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20237782
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6557618
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1091000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2139000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
893000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1701000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
438000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.93
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4315554
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6387121
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1262000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2655000
us-gaap Restructuring Costs
RestructuringCosts
1584000
CY2022 us-gaap Restructuring Costs
RestructuringCosts
0
CY2023Q3 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5609000
CY2022Q4 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6764000
CY2023Q3 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
329000
CY2022Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
335000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8784000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9754000
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2023Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.054
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.57
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1249000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
131000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
44000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1155000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1286000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
44000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
54000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
65000
us-gaap Operating Lease Expense
OperatingLeaseExpense
138000
us-gaap Operating Lease Expense
OperatingLeaseExpense
201000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
54000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
65000
us-gaap Operating Lease Cost
OperatingLeaseCost
138000
us-gaap Operating Lease Cost
OperatingLeaseCost
201000
us-gaap Operating Lease Payments
OperatingLeasePayments
97000
us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1310000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
53000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
195000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
217000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
220000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
857000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1542000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
256000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1286000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
2.095
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27600000
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.97
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2023Q3 grtx Stock Issued During Period Shares Of Common Stock Warrants Exercised
StockIssuedDuringPeriodSharesOfCommonStockWarrantsExercised
1020000
grtx Stock Issued During Period Shares Of Common Stock Warrants Exercised
StockIssuedDuringPeriodSharesOfCommonStockWarrantsExercised
1020000
CY2023Q3 grtx Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
2000000
grtx Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
2000000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1390000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1750000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4373000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5428000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5783185
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.86
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2378700
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.927
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0206
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
2309000
us-gaap Payments For Restructuring
PaymentsForRestructuring
725000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
1584000

Files In Submission

Name View Source Status
grtx-20230930_cal.xml Edgar Link unprocessable
0000950170-23-063361-index-headers.html Edgar Link pending
0000950170-23-063361-index.html Edgar Link pending
0000950170-23-063361.txt Edgar Link pending
0000950170-23-063361-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grtx-20230930.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
grtx-20230930.xsd Edgar Link pending
grtx-ex10_1.htm Edgar Link pending
grtx-ex31_1.htm Edgar Link pending
grtx-ex31_2.htm Edgar Link pending
grtx-ex32_1.htm Edgar Link pending
grtx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
grtx-20230930_lab.xml Edgar Link unprocessable
grtx-20230930_pre.xml Edgar Link unprocessable
grtx-20230930_def.xml Edgar Link unprocessable
grtx-20230930_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending